Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–19 patients who were consecutively admitted b...

Full description

Bibliographic Details
Main Authors: Tariq Kewan, Fahrettin Covut, Mohammed J. Al–Jaghbeer, Lori Rose, K.V. Gopalakrishna, Bassel Akbik
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:EClinicalMedicine
Subjects:
Coronavirus
SARS–CoV–2
Interleukin 6
Tocilizumab
Cytokine release syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020301620

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020301620

Similar Items